The OsteoStrand™ Plus Family Has Grown: Now Announcing the Launch of OsteoStrand Plus C! Today marks the full commercial launch of the newest addition to the Biologics Portfolio – OsteoStrand Plus C. This new 100% human tissue product combines the same DBM fibers and Accell™ Bone Matrix of OsteoStrand Plus, now with the addition of cancellous chips. Through extensive research, we identified a specific ratio of DBM fibers to chips and the size of chips that addresses the competing clinical requirements for graft osteoinductivity, flowability, and packability. We also demonstrate the mechanical benefit of this cancellous-containing graft formulation that contributes to load transfer through the graft material, an effect not observed with 100% DBM fiber formulations.* This new addition to the portfolio builds on our commitment to providing best-in-class products that are backed by science across the major market segments. Product available to order now! Visit https://lnkd.in/gd7BRrwB to learn more about OsteoStrand Plus C. *Lombardo, J., Marshall, B., Eisele, E., Larson, M., Russell, N. (2024). Optimized Formulation of Cancellous Chips in OsteoStrand Plus C Imparts Mechanical Advantage Over 100% DBM Fiber Graft [White Paper]. Orthofix Medical Inc.
Orthofix’s Post
More Relevant Posts
-
The OsteoStrand™ Plus Family Has Grown: Now Announcing the Launch of OsteoStrand Plus C! Today marks the full commercial launch of the newest addition to the Biologics Portfolio – OsteoStrand Plus C. This new 100% human tissue product combines the same DBM fibers and Accell™ Bone Matrix of OsteoStrand Plus, now with the addition of cancellous chips. Through extensive research, we identified a specific ratio of DBM fibers to chips and the size of chips that addresses the competing clinical requirements for graft osteoinductivity, flowability, and packability. We also demonstrate the mechanical benefit of this cancellous-containing graft formulation that contributes to load transfer through the graft material, an effect not observed with 100% DBM fiber formulations.* This new addition to the portfolio builds on our commitment to providing best-in-class products that are backed by science across the major market segments. Product available to order now! Visit https://lnkd.in/gd7BRrwB to learn more about OsteoStrand Plus C. *Lombardo, J., Marshall, B., Eisele, E., Larson, M., Russell, N. (2024). Optimized Formulation of Cancellous Chips in OsteoStrand Plus C Imparts Mechanical Advantage Over 100% DBM Fiber Graft [White Paper]. Orthofix Medical Inc.
-
-
The Zetasizer is getting an exciting upgrade… 👀 If you work with nanoparticles and colloids, you know how helpful zeta potential and molecular weight measurements are for indicating, predicting, and optimizing dispersion stability. ✨ With its combined Dynamic Light Scattering (DLS), Electrophoretic Light Scattering (ELS) and Static Light Scattering (SLS) capabilities, the Zetasizer ensures accuracy and repeatability even with complex samples – all with minimal training 👩🔬 The next innovation takes these benefits to the next level. Think increased productivity, fewer sample handling errors, and improved ease of use! Register now to be amongst the first to find out about the latest innovation for the Zetasizer 🔗https://bit.ly/3vsOcze Malvern Panalytical Pharmaceuticals #MalvernPanalytical #Zetasizer #Webinar
-
: Ophthalmic drug developers: are you considering a sterile eye ointment? The eye is a complex instrument, with multiple defense mechanisms for the tissues targeted by many drugs. Increasing the viscosity of ophthalmic drugs to create ointments can lengthen the drug’s contact time with the targeted tissue and reduce drainage. But formulation and production of ointments involve complicated manufacturing processes. Here are some of the factors to consider when developing a manufacturing process for ophthalmic ointments. https://bit.ly/3J8vnEp #pharma #drugmanufacturing
-
-
Pharmaceutical Technical Key Account Manager @ GATTEFOSSÉ | Sales, Technical Expertise
😯 Another Amazing Application for Compritol® 888 ATO! Indeed, Gattefossé Pharmaceuticals versatile excipient Compritol® 888 ATO is known for its role as a sustained-release agent and lubricant—but did you know it’s also perfect for fabricating solid lipid nanoparticles (SLNs)? SLNs are nanoscale lipid-based particles that bring substantial advantages to drug delivery: 👉 Enhanced bioavailability 👉 Protection from enzymatic degradation 👉 Controlled, sustained release 👉 Versatility, with the ability to encapsulate various drugs, including hydrophilic, lipophilic, and poorly soluble compounds. Explore an example of this cutting-edge formulation technology in a recent study featuring our excipients: Compritol® 888 ATO, Precirol® ATO 5, Geleol™ Mono and Diglycerides, and Gelucire® 43/01 - https://lnkd.in/d-3KxQez Discover more about Compritol® 888 ATO: https://lnkd.in/dq8Cc56t #Gattefossé #Pharmaceuticals #SLN #Bioavailbility #Protection #SustainRelease #Encapsulation #Innovation #DrugDelivery #Excipients
😯Yet another use of Compritol® 888 ATO?! Indeed, our star excipient Compritol® 888 ATO can be used as a sustained-release agent, as a lubricant… But did you know it could also be used for the fabrication of solid lipid nanoparticles (SLN)? SLNs are nanoscale particles made from lipids. They offer several advantages for drug delivery: 👉 Improved bioavailability 👉 Protection from enzymatic degradation 👉 Sustained release 👉 Versatility, as SLNs can encapsulate a wide range of drugs, including hydrophilic, lipophilic, and poorly soluble compounds. Discover an example of this powerful formulation technology in a recent scientific article that used our excipients: Compritol® 888 ATO, Precirol® ATO 5, Geleol™ Mono and Diglycerides and Gelucire® 43/01. https://lnkd.in/d-3KxQez And access Compritol® 888 ATO product page: https://lnkd.in/dq8Cc56t #gattefossé #pharmaceuticals #SLN
-
Snail mucin contains anti-inflammatory components, making it suitable for sensitive or acne-prone skin by calming redness and reducing inflammation. Overall, it’s a versatile ingredient that contributes to skin hydration, repair, and a smoother complexion. Share your thoughts….
A paper published in Pharmaceutics MDPI, assesses a novel lubricating multimolecular ophthalmic solution derived from snail mucus, examining its mucoadhesive and regenerative properties. The research, mentioned in National Geographic, explores the anti-inflammatory and analgesic potential for managing dry eye disease (DED) using snail mucus. Beyond DED management, snail mucus has also become a phenomenon in the skincare industry, boasting a 2022 global market value of approximately USD 555 million. Researchers are continuously unlocking the diverse health and pharmaceutical benefits of snail mucus. Read more about this research: https://brnw.ch/21wG7r4 or view the news story: https://brnw.ch/21wG7r3 #snailmucus #dryeyedisease #openaccess
Snail mucin is a skin care phenomenon—but does it really work?
-
A paper published in Pharmaceutics MDPI, assesses a novel lubricating multimolecular ophthalmic solution derived from snail mucus, examining its mucoadhesive and regenerative properties. The research, mentioned in National Geographic, explores the anti-inflammatory and analgesic potential for managing dry eye disease (DED) using snail mucus. Beyond DED management, snail mucus has also become a phenomenon in the skincare industry, boasting a 2022 global market value of approximately USD 555 million. Researchers are continuously unlocking the diverse health and pharmaceutical benefits of snail mucus. Read more about this research: https://brnw.ch/21wG7r4 or view the news story: https://brnw.ch/21wG7r3 #snailmucus #dryeyedisease #openaccess
Snail mucin is a skin care phenomenon—but does it really work?
-
What Drives Fullerene's Growth in the Medical and Pharmaceutical Industries? Fullerenes are transforming the #medical and #pharmaceutical industries with their unique properties. Their potential in #drugdelivery, antioxidant applications, #diagnosticimaging, and tissue engineering presents exciting opportunities. As #research advances and demand for innovative #healthcare solutions grows, fullerenes are set to become integral components in cutting-edge medical applications and set to drive significant advancements and growth in these sectors. For more Information: https://lnkd.in/d8XpTdiH Key Market Players Solenne BV NetScientific PLC Nano-C, Inc. BuckyLabs SES Research Inc. Nanografi Nano Technology IoLiTec Ionic Liquids Technologies GmbH #AMR #Fullerenes #MedicalInnovation #Antioxidants #TissueEngineering #Nanomaterials #PharmaMarket #HealthcareAdvancements #NeurodegenerativeDiseases #CancerTreatment #RegenerativeMedicine
-
The Zetasizer is getting an exciting upgrade… 👀 If you work with nanoparticles and colloids, you know how helpful zeta potential and molecular weight measurements are for indicating, predicting, and optimizing dispersion stability. ✨ With its combined Dynamic Light Scattering (DLS), Electrophoretic Light Scattering (ELS) and Static Light Scattering (SLS) capabilities, the Zetasizer ensures accuracy and repeatability even with complex samples – all with minimal training 👩🔬 The next innovation takes these benefits to the next level. Think increased productivity, fewer sample handling errors, and improved ease of use! Register now to be amongst the first to find out about the latest innovation for the Zetasizer 🔗 https://lnkd.in/dw_FNaRD Malvern Panalytical Pharmaceuticals #MalvernPanalytical #Zetasizer #Webinar
-
Gentle reminder for next weeks Webinar
Lipid nanoparticle (#LNP) formulation processes begin on a small scale, often with homemade or bench-top setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems. In our #webinar on July 11, our #drugdelivery experts Michael Parr and Alex Leung outline the factors that formulators need to consider when scaling up novel #lipidnanoparticle systems. Learn about parameters that affect LNP formation, such as flow rate, solvent removal, buffer exchange, and the risk factors when changing equipment. Whether you work in formulation, R&D, or business development, this webinar will help you navigate the many hurdles of LNP scale-up. Curious? Register now at https://lnkd.in/eNPba4bF. #lipids #parenteral #rna #mrna #injectables #implants #cmo #cdmo #contractmanufacturing #outsourcing #biopharma #pharma #healthcare #webcast Evonik
-
-
How can you minimize pain at the injection site for better patient comfort? Discover the key factors influencing injection site pain and how to address them to optimize formulations and improve patient experience. Our latest blog post explores the impact of device type, formulation, and patient-specific factors. Learn how Genoskin’s cutting-edge platforms can predict and mitigate pain effectively. 👉🏻https://lnkd.in/gP_Wjtb7 Stay tuned to learn how Genoskin’s innovative ex vivo human skin platforms can predict injection site pain, helping you optimize formulations and enhance patient comfort. #Neuroinflammation #DrugDevelopment #Biotech #Pharma #Innovation #PatientSafety #injection
